Showing 881-890 of 1938 results for "".
Mid-Face Filler Pearls
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/mid-face-filler-pearls/18537/Shannon Humphrey, MD shares three pearls for avoiding the filler complication patients fear the most in the mid-face: unnatural results. You must have a plan, she says, to avoid treating the cheeks as an island rather than as part of the full face.A Global Approach to Perioral Rejuvenation
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/a-global-approach-to-perioral-rejuvenation/18615/Joel L.Cohen, MD, Director of AboutSkin Dermatology and DermSurgery in Englewood and Lone Tree, CO, discusses the new thinking about perioral rejuvenation at the Cosmetic Surgery Forum 2015 in Las Vegas. He shares techniques for a combination approach for the best, most natural results for enhancingDerm Insider: Ethics and Industry: How to Manage Relationships with Pharma
https://practicaldermatology.com/topics/practice-management/derm-insider-ethics-and-industry-how-to-manage-relationships-with-pharma/19029/In this edition, host Neal Bhatia, MD and guests Tom Prunty and James Q. Del Rosso, DO tackle the ethics of industry relationships. They discuss the nuances and challenges of physicians fostering appropriate relationships with pharmaceutical manufacturers amid an increasingly stringent regulatory laManaging Office Politics
https://practicaldermatology.com/topics/practice-management/managing-office-politics/19101/Neal Bhatia, MD, Co-Chief Medical Editor of Practical Dermatology® magazine, shares pearls for successfully understanding and navigating the scope of office politics and relationships. DermTube's coverage of the AAD's 2014 Summer Meeting is not endorsed by or affiliated with the American Academy ofDWTV Extra: Phase 3 Data on Roflumilast for AD, PsO
https://practicaldermatology.com/series/dermwire-tv/dwtv-extra-phase-3-data-on-roflumilast-for-ad-pso/35925/Study investigator Melinda Gooderham, MD, talks about the Phase 3 trials of roflumilast cream 0.15% for adults and children down to age 6 with atopic dermatitis and roflumilast foam 0.3% for patients older than 12 with psoriasis of the scalp and body.DWTV Extra: New Tapinarof Data for AD
https://practicaldermatology.com/series/dermwire-tv/dwtv-extra-new-tapinarof-data-for-ad/33940/Linda Stein Gold, MD, discusses the results from the Phase 3 ADORING 3 open-label, long-term extension study evaluating tapinarof cream, 1% once daily in children as young as 2 and adults with atopic dermatitis, presented at the 2025 American Academy of Dermatology (AAD) Annual Meeting in OrlandoDr. Anderson on New Tech That ‘Could be Revolutionary’ at Maui Derm
https://practicaldermatology.com/conferences/maui-derm-hawaii-2025/dr-anderson-on-new-tech-that-could-be-revolutionary-at-maui-derm/32921/In-vivo microscopy that will change how dermatologists practice and potentially revolutionary drug delivery systems were among the technologies highlighted by R. Rox Anderson, MD, PhD, during “Innovation in Dermatology 2025: A Look Into the Future of Dermatology” at the Maui Derm Hawaii 2025 meetingEczematous Dermatitis: Dr. Zirwas
https://practicaldermatology.com/programs/practical-dermatology/eczematous-dermatitis-dr-zirwas/32689/Matthew Zirwas, MD, talks about the therapeutic strategies for non-atopic dermatitis—particularly hand dermatitis and facial dermatitis—that he covered during "Eczematous Dermatitis Update 2025: Contact, Hand, Head and Neck, Eyelid and More" at Maui Derm 2025.Combining Aesthetic Treatments: Dr. Chilukuri
https://practicaldermatology.com/conferences/maui-derm-hawaii-2025/combining-aesthetic-treatments-dr-chilukuri/32692/Suneel Chilukuri, MD, talks about some of the new regenerative options and combining them with devices and other therapies, as discussed in "What's My Treatment? How to Combine Dermal Filler, Neuromodulators, Laser/Light/RF Devices/Microneedling and Cosmeceuticals Symposium" at Maui Derm 2025.Get Ready for JAK Inhibitors
https://practicaldermatology.com/topics/psoriasis/get-ready-for-jak-inhibitors/19928/JAK inhibitors are going to change the way we think about refractory disease, says Brett King, MD. He addresses the significant increase in study of these agents and the many potential uses for refractory diseases like alopecia, atopic dermatitis, vitiligo, psoriasis, and more.